Compare IMMP & ODC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | ODC |
|---|---|---|
| Founded | 1987 | 1941 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous manufacturing industries |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.9M | 790.1M |
| IPO Year | N/A | N/A |
| Metric | IMMP | ODC |
|---|---|---|
| Price | $2.79 | $49.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 95.4K |
| Earning Date | 02-22-2026 | 12-08-2025 |
| Dividend Yield | N/A | ★ 1.61% |
| EPS Growth | N/A | ★ 17.33 |
| EPS | N/A | ★ 3.63 |
| Revenue | $3,306,742.00 | ★ $478,113,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.01 |
| Revenue Growth | ★ 31.28 | 5.29 |
| 52 Week Low | $1.32 | $40.66 |
| 52 Week High | $3.53 | $69.76 |
| Indicator | IMMP | ODC |
|---|---|---|
| Relative Strength Index (RSI) | 72.91 | 40.25 |
| Support Level | $2.52 | $45.61 |
| Resistance Level | $2.86 | $54.16 |
| Average True Range (ATR) | 0.28 | 2.39 |
| MACD | 0.05 | 0.12 |
| Stochastic Oscillator | 58.61 | 43.82 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.